Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Clin Cancer Res. 2014 Aug 14;20(19):5009–5022. doi: 10.1158/1078-0432.CCR-14-1122-T

Figure 5. MVA-EL vaccination of NPC patients stimulates broad T-cell immunity specific for multiple epitopes in EBNA1 and LMP2.

Figure 5

A. Diagram showing the design of the EBNA1/LMP2 fusion protein encoded by the MVA-EL vaccine. The location of defined epitopes used as peptide targets in IFNγ ELISpot assays are also indicated. HLA class I-restricted CD8 T cell epitopes are shown above the fusion protein; HLA class II-restricted CD4 T-cell epitopes are shown below. B. Diagram showing the breadth of T-cell responses stimulated by MVA-EL. Epitope location is represented by black (HLA class I) and white (HLA class II) lines on the fusion protein. Bar height above (HLA class I) and below (HLA class II) the fusion protein indicates the number of donors from the Hong Kong and UK phase IA trials that responded to the indicated epitope.